Idiopathic pulmonary fibrosis: integration of modern diagnostic and therapeutic algorithms
- 19 May 2026
- journal article
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 1,p. 189-199
Abstract
Idiopathic pulmonary fibrosis (IPF) is a severe disease with an unfavorable prognosis, requiring a comprehensive, multidisciplinary approach to diagnosis and treatment. Its clinical presentation is dominated by nonspecific symptoms, primarily progressive dyspnea and cough, which clinicians may attribute to similar conditions (COPD, CHF, and others), thereby delaying verification of the diagnosis. Early diagnosis and the timely initiation of targeted therapy are crucial for improving patient outcomes. Antifibrotic medications (pirfenidone and nintedanib) are essential in IPF treatment, slowing pulmonary function decline and improving survival, particularly when initiated early. They exhibit comparable safety and efficacy profiles.Keywords
This publication has 11 references indexed in Scilit:
- Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosisRespiratory Research, 2025
- Prospects of pirfenidone use in idiopathic pulmonary fibrosis and progressive pulmonary fibrosisMeditsinskiy sovet = Medical Council, 2025
- Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research)Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2024
- Респираторная медицина : руководство : в 4 т. 3-е изд., доп. и перераб. Т. 3.2024
- Effects of home‐based telerehabilitation‐assisted inspiratory muscle training in patients with idiopathic pulmonary fibrosis: A randomized controlled trialRespirology, 2024
- Idiopathic pulmonary fibrosis: a clinical case of long-term follow-upConsilium Medicum, 2022
- Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosisPULMONOLOGIYA, 2022
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice GuidelineAmerican Journal of Respiratory and Critical Care Medicine, 2022
- Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment withN-acetylcysteineEuropean Respiratory Journal, 2021
- Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantationScientific Reports, 2019